报告题目：Targeting sphingolipid signalling for stroke 报 告 人：Christian Waeber, Senior Lecturer in Pharmacology (School of Pharmacy, University College Cork, Ireland) 报告时间：2017年4月7日（周五） 14:00 报告地点：独墅湖校区二期云轩楼2301室 Dr. Christian Waebe简介
Christian Waeber received his master’s degree in biochemistry from the University of Fribourg (Switzerland) and then worked as a Ph.D. student at Novartis Basel, where he characterized the pharmacological profile, signalling pathways and brain distribution of 5-HT1D receptors. He was awarded a Ph.D. in biochemistry in 1991 by the University of Fribourg. After a first post-doctoral fellowship in the laboratory of Joel Bockaert at the “CNRS-INSERM Center for Pharmacology and Endocrinology” in Montpellier (France), DrWaeber moved in 1993 to Harvard Medical School to characterize the pharmacological profile of 5-HT receptors mediating the effects of antimigraine drugs. Fifteen years ago, DrWaeber switched topics, largely abandoning research on 5-HT to focus on the role of sphingosine-1-phosphate receptors in blood vessels and brain. His research was instrumental in demonstrating the therapeutic potential of the S1P agonist and Multiple Sclerosis drug fingolimod for the acute treatment of stroke. After 20 years in Boston, DrWaeber joined School of Pharmacy,University College Cork (Ireland) in 2013. DrWaeber’s 120+ original publicationshave been cited more than 16000 times. |
(药学院)
